Sedation Management with Lorazepam and Midazolam
Introduction to Sedation Options
- The American College of Critical Care Medicine recommends lorazepam as the preferred benzodiazepine due to its predictable duration and safety profile 1, 3
- Lorazepam is the first-line agent recommended for sedation in patients on ECMO, while midazolam should be avoided due to its high sequestration in the ECMO circuit, making it unreliable 1
Pharmacokinetic Advantages of Lorazepam
- Lorazepam has an intermediate half-life of 8-15 hours with no active metabolites, providing more predictable effects and easier titration 2, 3, 4
- Lorazepam undergoes direct glucuronidation with no active metabolites, making it safer in patients with renal failure 5, 2, 3
Safety Considerations
- Parenteral formulations of lorazepam contain propylene glycol as a diluent, which can cause metabolic acidosis and acute kidney injury 3, 4
- Both agents cause dose-dependent respiratory depression, especially when combined with opioids or alcohol 2, 3, 4
Special Populations
- In elderly patients, the clearance of benzodiazepines decreases with age, making prolonged effects more pronounced 2
- Lorazepam and midazolam both present a risk of paradoxical reactions of rage in pediatric patients 3
Practical Decision Algorithm
- For patients on ECMO or ICU with prolonged sedation, use lorazepam as the first line 1, 3
- Monitor osmolar gap if total daily dose >1 mg/kg 3
- Avoid midazolam due to sequestration in the circuit 1